NL-OMON33506已完成不适用
ong-term safety of trastuzumab in patients with HER2-positive breast cancer - Long-term safety of trastuzumab
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+ using the HercepTestTM, or gene amplification by fluorescence in situ hybridization, or chromogenic in situ hybridization (CISH)
排除标准
- •Pregnancy or breast feeding
研究者
相似试验
招募中
2 期
Trastuzumab Emtansine in patients with advanced HER2-positive extramammary Paget's disease: a phase ll trialJPRN-jRCTs031200064Funakoshi Takeru16
已完成
1 期
Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancerBreast cancerJPRN-UMIN000034475Kitasato University School of Medicine9
已完成
1 期
Assessment of safety on trastuzumab with varied dilution solution volume in HER2 positive breast cancerBreast cancerJPRN-UMIN000008983Kitasato University School of Medicine18
招募中
2 期
HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patientsEsophageal Cancer2024-516318-40-02Rigshospitalet, Frederiksberg Hospital24
进行中（未招募）
不适用
Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study. - Dose optimization of TrastuzumabEUCTR2007-006060-29-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO